Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
The Chemours Company is a specialty chemicals business based in the US. The Chemours Company shares (CC) are listed on the NYSE and all prices are listed in US Dollars. The Chemours Company employs 6,500 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$30.64|
|52-week range||$18.83 - $37.67|
|50-day moving average||$30.68|
|200-day moving average||$32.49|
|Wall St. target price||$40.83|
|Dividend yield||$1 (3.23%)|
|Earnings per share (TTM)||$1.52|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||-0.87%|
|1 month (2021-09-17)||2.99%|
|3 months (2021-07-19)||-0.78%|
|6 months (2021-04-19)||2.65%|
|1 year (2020-10-19)||35.04%|
|2 years (2019-10-18)||102.24%|
|3 years (2018-10-19)||35.87|
|5 years (2016-10-19)||88.90%|
Valuing The Chemours Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of The Chemours Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
The Chemours Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, The Chemours Company shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
The Chemours Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into The Chemours Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
The Chemours Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $785 million.
The EBITDA is a measure of a The Chemours Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5.7 billion|
|Operating margin TTM||8.16%|
|Gross profit TTM||$1.1 billion|
|Return on assets TTM||3.98%|
|Return on equity TTM||32.84%|
|Market capitalisation||$5.1 billion|
TTM: trailing 12 months
There are currently 9.4 million The Chemours Company shares held short by investors – that's known as The Chemours Company's "short interest". This figure is 29.1% up from 7.2 million last month.
There are a few different ways that this level of interest in shorting The Chemours Company shares can be evaluated.
The Chemours Company's "short interest ratio" (SIR) is the quantity of The Chemours Company shares currently shorted divided by the average quantity of The Chemours Company shares traded daily (recently around 1.8 million). The Chemours Company's SIR currently stands at 5.19. In other words for every 100,000 The Chemours Company shares traded daily on the market, roughly 5190 shares are currently held short.
However The Chemours Company's short interest can also be evaluated against the total number of The Chemours Company shares, or, against the total number of tradable The Chemours Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case The Chemours Company's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 The Chemours Company shares in existence, roughly 60 shares are currently held short) or 0.0605% of the tradable shares (for every 100,000 tradable The Chemours Company shares, roughly 61 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against The Chemours Company.
Find out more about how you can short The Chemours Company stock.
Dividend payout ratio: 33.33% of net profits
Recently The Chemours Company has paid out, on average, around 33.33% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.23% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), The Chemours Company shareholders could enjoy a 3.23% return on their shares, in the form of dividend payments. In The Chemours Company's case, that would currently equate to about $1 per share.
While The Chemours Company's payout ratio might seem fairly standard, it's worth remembering that The Chemours Company may be investing much of the rest of its net profits in future growth.
The Chemours Company's most recent dividend payout was on 14 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 12 August 2021 (the "ex-dividend date").
Over the last 12 months, The Chemours Company's shares have ranged in value from as little as $18.8333 up to $37.6745. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while The Chemours Company's is 2.1794. This would suggest that The Chemours Company's shares are significantly more volatile than the average for this exchange and represent a higher risk.
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications. The Thermal & Specialized Solutions segment offers of refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment provides polymers and advanced materials. Its Chemical Solutions segment offers industrial chemicals used in gold production, industrial, and consumer applications. The company sells its products through direct channels, as well as through a network of resellers and distributors.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.